Researchers at Mount Sinai have developed a novel approach to cancer immunotherapy, injecting immune stimulants directly into a tumor to teach the immune system to destroy it and other tumor cells throughout the body.
The “in situ vaccination” worked so well in patients with advanced-stage lymphoma that it is also undergoing trials in breast and head and neck cancer patients, according to a study published in Nature Medicine in April.
The treatment consists of administering a series of immune stimulants directly into one tumor site. The first stimulant recruits important immune cells called dendritic cells that act like generals of the immune army. The second stimulant activatesthe dendritic cells, which then instruct T cells, the immune system’s soldiers, to kill cancer cells and spare non-cancer cells. This immune army learns to recognize features of the tumor cells so it can seek them out and destroy them throughout the body, essentially turning the tumor into a cancer vaccine factory.
“The in situ vaccine approach has broad implications for multiple types of cancer,” said lead author Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “This method could also increase the success of other immunotherapies such as checkpoint blockade.”
After testing the lymphoma vaccine in the lab, it was tested in 11 patients in a clinical trial. Some patients had full remission from months to years. In lab tests in mice, the vaccine drastically increased the success of checkpoint blockade immunotherapy, the type of immunotherapy responsible for the complete remission of former President Jimmy Carter’s cancer and the focus of the 2018 Nobel Prize in Medicine.
A clinical trial for lymphoma, breast, and head and neck cancer patients opened in March to test the vaccine with checkpoint blockade drugs. Because the combined immune therapy was at least three times more powerful than either checkpoint blockade or the vaccine by themselves, researchers are extremely optimistic about how effective this may be in patients in this new trial. The in situ vaccine is also being tested in the lab in liver and ovarian cancer.
Learn more: Mount Sinai Researchers Develop Treatment That Turns Tumors Into Cancer Vaccine Factories
The Latest on: Cancer immunotherapy
[google_news title=”” keyword=”cancer immunotherapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer immunotherapy
- AI-driven model identifies potent cancer-killing immune cells for personalized immunotherapyon May 7, 2024 at 9:46 pm
Using artificial intelligence, Ludwig Cancer Research scientists have developed a powerful predictive model for identifying the most potent cancer killing immune cells for use in cancer ...
- Unveiling Vitamin D’s Hidden Power Against Canceron May 7, 2024 at 3:30 am
Study finds that vitamin D boosts gut health and cancer treatment success in mice, indicating new avenues for enhancing immunotherapy. A recent study in mice reveals that dietary vitamin D can ...
- Study Uncovers a Cause of Cancer Immunotherapy Roadblockson May 7, 2024 at 1:46 am
A study led by Yale scientists, investigated the potential causes associated with T cell exclusion using a genome-wide screen of more than 1,000 human proteins.
- Precision medicine tool predicts breast cancer immunotherapy responseon May 6, 2024 at 10:30 am
New InteractPrint tool analyzes how breast cancer epithelial cells impact cancer-immune interactions, enabling prediction of immune checkpoint inhibition response.
- Study uncovers at least one cause of roadblocks to cancer immunotherapyon May 6, 2024 at 9:39 am
T cells—the body's foot soldiers against invaders, ranging from everyday infections to cancers—are integral to many successful immunotherapies. However, a frustrating factor is that immunotherapies do ...
- Fighting Cancer: A Basic Guide To Checkpoint Inhibitorson May 6, 2024 at 6:30 am
People with cancer may encounter checkpoint inhibitors as a treatment option but may not know where to start. This article can help you learn more.
- Combo Therapy May Be Advance Against Liver Canceron May 6, 2024 at 3:00 am
A new combination therapy appears to boost the response rate for liver cancer patients receiving immunotherapy, accordin ...
- Many Patients With Advanced MCC Not Receiving Immunotherapyon May 5, 2024 at 9:36 pm
Despite improved survival rates and guideline recommendations, many eligible patients with metastatic Merkel cell carcinoma are not receiving immunotherapy.
- Immunotherapy: A Beacon of Hope in Cancer Treatmenton May 4, 2024 at 2:25 pm
Cancer, a disease that has plagued humanity for centuries, has finally met its match in immunotherapy, a revolutionary treatment that harnesses the power of the immune system to combat this deadly ...
- Pan-cancer analysis uncovers a new class of promising CAR T–cell immunotherapy targetson May 3, 2024 at 10:16 am
Targeting anti-cancer therapy to affect cancer cells but not healthy cells is challenging. For chimeric antigen receptor (CAR) T–cell immunotherapy, where a patient's own immune cells are ...
via Bing News